- Home
- FENC vs OABI Comparison
FENC vs OABI Comparison
Compare FENC & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- OABI
- Stock Information
- Founded
- FENC 1996
- OABI 2012
- Country
- FENC United States
- OABI United States
- Employees
- FENC 32
- OABI N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- FENC Health Care
- OABI Health Care
- Exchange
- FENC Nasdaq
- OABI Nasdaq
- Market Cap
- FENC 222.9M
- OABI 198.2M
- IPO Year
- FENC 2001
- OABI N/A
- Fundamental
- Price
- FENC $8.34
- OABI $1.70
- Analyst Decision
- FENC Strong Buy
- OABI Strong Buy
- Analyst Count
- FENC 2
- OABI 3
- Target Price
- FENC $13.00
- OABI $7.00
- AVG Volume (30 Days)
- FENC 83.2K
- OABI 1.1M
- Earning Date
- FENC 08-12-2025
- OABI 08-07-2025
- Dividend Yield
- FENC N/A
- OABI N/A
- EPS Growth
- FENC N/A
- OABI N/A
- EPS
- FENC N/A
- OABI N/A
- Revenue
- FENC $30,912,000.00
- OABI $26,744,000.00
- Revenue This Year
- FENC $0.85
- OABI N/A
- Revenue Next Year
- FENC $55.16
- OABI $45.65
- P/E Ratio
- FENC N/A
- OABI N/A
- Revenue Growth
- FENC N/A
- OABI 27.07
- 52 Week Low
- FENC $3.96
- OABI $1.22
- 52 Week High
- FENC $8.72
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- FENC 58.31
- OABI 55.82
- Support Level
- FENC $7.53
- OABI $1.55
- Resistance Level
- FENC $8.68
- OABI $1.73
- Average True Range (ATR)
- FENC 0.49
- OABI 0.11
- MACD
- FENC -0.04
- OABI 0.02
- Stochastic Oscillator
- FENC 63.18
- OABI 74.73
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.